Mark A. Wernham, MS, PA-C

Mark Wernham practices at Dermatology Associates of Ithaca in Cortland, New York.

Mark Wernham's NPI, 1205849981, was assigned on August 14, 2006. Mark Wernham graduated from Rutgers New Jersey Medical School in 2006. Mark Wernham holds New York license 019675-1.

Mark Wernham's primary practice is Dermatology Associates of Ithaca, at 3773 Luker Rd, Cortland, NY 13045 in Cortland County. The practice phone is (607) 257-1107.

Mark Wernham's primary practice is Dermatology Associates of Ithaca in Cortland, New York. Mark Wernham is also affiliated with Cayuga Medical Center. The medical group on file is Dermatology Associates of Ithaca. Dmand AI also links Mark Wernham to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Wernham practices, 2 sites in all. Vendor and product names are available with a free account.

Medical is Mark Wernham's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Mark Wernham is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Dmand AI has Mark Wernham's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cold sores or genital herpes, contact dermatitis, hives, itchy rashes and joint cyst among the conditions Mark Wernham treats.

CMS data shows 3,677 Medicare services from Mark Wernham across 11 procedure codes in 2024, for 1,036 Medicare patients. Medicare paid $110,282 for them. Every service was in an office.

CMS counts 1,036 Medicare patients who saw Mark Wernham in 2024. The largest group is 65 to 74, with 460 patients. 70% of them have high cholesterol, and 64% have high blood pressure. 9% are also on Medicaid. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mark Wernham's median patient age at 62, with 53% women.

In 2024, Mark Wernham wrote 919 Medicare Part D claims for 320 patients. 88% of them were for generic drugs. CMS names the drug for 804 of them, across 23 drugs with 11 or more claims each, at $366,701 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Mark Wernham for performance year 2024, reported as part of a group. Mark Wernham accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 22 general payments to Mark Wernham from 12 drug and device companies in 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $107.

Mark Wernham graduated from Rutgers New Jersey Medical School in 2006. Mark Wernham is a member of AAPA.